Vanguard Group’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.8M | Buy |
1,604,860
+29,266
| +2% | +$197K | ﹤0.01% | 2866 |
|
|
2025
Q1 | $14.2M | Buy |
1,575,594
+111,357
| +8% | +$1.01M | ﹤0.01% | 2659 |
|
|
2024
Q4 | $25.3M | Buy |
1,464,237
+241,052
| +20% | +$4.17M | ﹤0.01% | 2476 |
|
|
2024
Q3 | $19.5M | Buy |
1,223,185
+93,562
| +8% | +$1.5M | ﹤0.01% | 2598 |
|
|
2024
Q2 | $16.1M | Buy |
1,129,623
+50,715
| +5% | +$723K | ﹤0.01% | 2668 |
|
|
2024
Q1 | $15.3M | Buy |
1,078,908
+13,742
| +1% | +$195K | ﹤0.01% | 2725 |
|
|
2023
Q4 | $16.1M | Buy |
1,065,166
+44,849
| +4% | +$677K | ﹤0.01% | 2693 |
|
|
2023
Q3 | $16.1M | Buy |
1,020,317
+10,568
| +1% | +$167K | ﹤0.01% | 2638 |
|
|
2023
Q2 | $15.3M | Buy |
1,009,749
+81,084
| +9% | +$1.23M | ﹤0.01% | 2713 |
|
|
2023
Q1 | $13.5M | Buy |
928,665
+8,412
| +0.9% | +$122K | ﹤0.01% | 2783 |
|
|
2022
Q4 | $12.4M | Buy |
920,253
+50,106
| +6% | +$677K | ﹤0.01% | 2851 |
|
|
2022
Q3 | $13.7M | Buy |
870,147
+107,783
| +14% | +$1.7M | ﹤0.01% | 2801 |
|
|
2022
Q2 | $9.29M | Buy |
762,364
+331,960
| +77% | +$4.04M | ﹤0.01% | 3031 |
|
|
2022
Q1 | $4.04M | Buy |
430,404
+5,452
| +1% | +$51.2K | ﹤0.01% | 3628 |
|
|
2021
Q4 | $7.27M | Buy |
+424,952
| New | +$7.27M | ﹤0.01% | 3406 |
|